CD34+ selection: The basic component for graft engineering

Oncologist

Volumn 2, Issue 6, 1997, Pages 410-413

  Miltenyi, Stefan ^a  

^a MILTENYI BIOTEC GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN EXPRESSION; AUTOIMMUNE DISEASE; BIOMEDICAL ENGINEERING; BLOOD AUTOTRANSFUSION; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CELL SELECTION; CYTOPENIA; GENE THERAPY; GRAFT VERSUS HOST REACTION; HUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE SUBPOPULATION; UMBILICAL CORD BLOOD;

EID: 0031458098     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.2-6-410     Document Type: Review

References (15)

1. Civin CI, Strauss LC, Brovall C et al. Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J Immunol 1984;133:151-165.
2. Shpall EJ, Jones RB, Bearman SI et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral blood progenitors and growth factors on engraftment. J Clin Oncol 1984;12:28-36.
3. + cells selected with the Amgen cell selection system safely and rapidly engraft following high-dose chemotherapy for breast cancer. J Clin Oncol 1997;16:101a.
4. + marrow cells in patients with breast cancer or neuroblastoma. Blood 1991;77:1717-1722.
5. Goldman H. Peripheral blood stem cells for allografting. Blood 1995;85:1413-1415.
6. + cells with the Amgen cell selection system provides T, NK and tumor cell depletion of peripheral blood stem cells from breast cancer patients. Exp Hematol 1997;25:802a.
7. + T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow. Bone Marrow Transplant 1991;8:51-58.
8. Johnson BD, Brobyski WR, Truitt RL. Delayed infusion of non-donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. Bone Marrow Transplant 1993;11:329-336.
9. + T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Blood 1990;76:418-423.
10. Broxmeyer HE, Gluckman E, Auerbach AD et al. Human umbilical cord blood: a clinically useful source of transplantable hematopoietic stem/progenitor cells. Int J Cell Cloning 1990;8:76-91.
11. + cells is essential for optimal ex vivo expansion of umbilical cord blood cells. J Hematother 1997;6:145-150.
12. Silverstein LE, Jefferies LC. Placental blood banking. A new frontier in transfusion medicine. N Engl J Med 1996;335:199-201.
13. Gluckman EG, Rocha V, Chastang C. Use of cord blood cells for banking and transplant. The Oncologist 1997;2:340-343.
14. Krause DS Fackler MJ, Civin CL et al. CD34: structure, biology, and clinical utility. Blood 1996;87:1-13.
15. Champlin R, Giralt S, Przepiorka D et al. Selective depletion of CD8-positive T-lymphocytes for allogeneic bone marrow transplantation: engraftment, graft-versus-host disease and graft-versus-leukemia. In: Worthington-White DA, Gee AP, Gross S, eds. Advances in Bone Marrow Purging and Processing. New York: Wiley-Liss, Inc., 1992:385-398.